VC Fund Dossiers

Dick and Adam are the rare VCs who actually know what it's like to scale a rocket ship — they lived through Twitter's wild growth and all the chaos that comes with it. This makes them unusually helpful for founders hitting scaling walls, but they're also pretty selective and won't sugarcoat things if your metrics aren't there. They're particularly strong in AI infrastructure where their technical judgment and network really shine. The fund is still relatively new but has already landed some impressive logos. They tend to move fast on deals they like but can be tough to get in front of initially.

360 Capital is one of Europe's most successful old-school VC shops that actually delivers results—their Preligens exit to Safran for €220M in 2024 and backing Exotec to become France's first industrial unicorn proves they know how to pick winners and get liquidity. Founded in 1997, they've survived multiple cycles and have the conviction to back deep tech when others chase software. Fausto Boni is a genuine operator with McKinsey pedigree who sits on boards and gets his hands dirty. The dual Paris-Milan setup gives them unique access to Southern European talent that coastal VCs miss. Their 71% seed to Series A conversion rate (92% including exits) is exceptional. Watch for their climate tech focus with the new €140M 360 LIFE II fund—they're betting big on energy transition when others just talk about it.

3M Ventures is the rare corporate VC that actually knows what they're talking about when it comes to deep tech and manufacturing. They bring genuine technical expertise and can open doors to pilot programs with 3M's massive industrial customer base. The flip side? They move at corporate speed, decisions take forever, and there's always the strategic acquisition shadow hanging over everything. If your tech genuinely complements 3M's business, they're incredibly valuable partners. If not, you're probably better off with traditional VCs who won't spend six months debating internal synergies.

500 Global is the reformed bad boy of seed funds - they've cleaned up their act since the Dave McClure drama and become a legitimate global player. Christine Tsai running the show means actual operational discipline, which wasn't always the case in the early wild west days. They're genuinely helpful post-investment with real accelerator resources and an impressive mentor network. The trade-off is you're one of hundreds in their portfolio, so don't expect white-glove attention unless you're clearly breaking out. Their global reach is real - if you're building in emerging markets or need international connections, they're actually useful.

500 Global MENA is part of the broader 500 Global network, so you get access to their global platform and resources, which is genuinely valuable for MENA startups looking to expand internationally. They understand the regulatory complexity of operating across multiple Middle Eastern markets better than most international VCs stumbling into the region. However, they're not writing huge checks - expect smaller initial investments with follow-on potential. The partners have solid operational backgrounds, but this isn't a prestige brand that will wow other investors. They're workmanlike investors who will actually help you navigate local market challenges rather than just throw money and expect magic.

7wire is one of the few healthcare-only funds that actually gets it - they're not generalist VCs pretending to understand healthcare. Shapiro and Garrity have real operational chops and extensive healthcare networks that matter when you're trying to sell to hospitals and health systems. They're particularly strong on go-to-market strategy and regulatory navigation. The downside? They can be quite selective and move slower than typical VCs due to their deep diligence process. If you're building outside of traditional healthcare delivery models, they might not be the right fit.

83North is the scrappy European fund that actually delivers. While they don't have the brand cache of Sequoia or a16z, their portfolio performance speaks for itself - they backed Klarna when it was unfashionable and rode it to a $46B valuation. Their partners are genuinely hands-on and won't ghost you after the check clears. The downside? Their ticket sizes have grown with their success, so if you're raising a small seed round, look elsewhere. They're also pretty thesis-driven, so if your company doesn't fit their current focus areas, you'll get a quick no rather than wasting time.

a16z Bio is the grown-up in the room for bio/healthtech investing. Unlike traditional biotech VCs who get spooked by tech, or tech VCs who don't understand FDA pathways, these folks actually get both sides. The partners have real operating experience and clinical backgrounds, which means they won't ask you to pivot to B2C when your B2B2C model hits regulatory hurdles. They're patient capital with 10+ year timelines, but expect you to show computational moats, not just wet lab progress. The a16z brand opens doors with pharma partnerships, but you'll need to prove platform scalability, not just single-asset potential.

This is a16z trying to buy their way into healthcare credibility, and it's actually working pretty well. The partners are solid — Vineeta knows her stuff technically, Julie has real operator experience, and they're building a legitimate healthcare network. They move fast when they want something and can write big checks, but you're getting the full a16z treatment: high expectations, lots of portfolio company cross-pollination, and pressure to think big. The flip side is they sometimes push companies to scale too aggressively before product-market fit is locked in. If you want maximum acceleration and can handle the intensity, they're legit.

a16z Crypto is the 800-pound gorilla of crypto VC with genuine conviction, not just FOMO money. They've stayed consistent through multiple crypto winters while others fled. The upside: massive network effects, regulatory connections, and they actually understand the technology. The downside: you're competing with their 150+ portfolio companies for attention, and their brand association might hurt if crypto sentiment sours. Chris Dixon is a true believer who will go to bat for you, but expect very high growth expectations given their fund size. They're surprisingly founder-friendly for such a big fund, but don't expect white glove treatment unless you're clearly a breakout company.

Aavishkaar is impact investing's OG in India - they've been doing 'business with purpose' since 2001 when most VCs were still chasing pure tech plays. While Aavishkaar Capital does focus on sustainable development goals, it stands at 3x Gross Multiple of Investment Capital (MOIC), in terms of returns. "We clock approximately 25 percent in terms of IRR as well. I don't think returns can be compromised just because we are called impact investors," Sushma says. That's solid performance for impact investing. But here's the thing - they're pivoting hard into climate and deeptech now, which means longer hold periods and more patient capital requirements. Track record is below average ... Less insightful than your average VC. Domain know-how limited to 1-2 sectors at best. Stingy culture - some Glassdoor reviews suggest internal culture issues and limited sector expertise beyond their core focus areas. They're great if you're building for underserved markets in financial inclusion or agtech, but expect a very thesis-driven, impact-first approach that may not suit pure growth plays.

AbbVie Ventures is the corporate VC arm that actually gets it - they move fast for a pharma giant and their checks are meaningful. The team has real scientific chops and can open doors at AbbVie proper, which matters when you need partnership or acquisition conversations. That said, they're not leading rounds and their investment committee can get spooked by anything too far outside AbbVie's wheelhouse. If your biotech aligns with their therapeutic areas, they're gold. If not, don't waste time - they stick to their knitting religiously.

Here's the deal: Abingworth got acquired by Carlyle in 2022 for $2 billion AUM, which means you're now dealing with a PE-backed entity, not an independent VC. This changes the dynamic entirely. The good news? They have serious biotech chops - 179 companies invested, 70 IPOs, 46 M&As, and their portfolio companies have secured 26 FDA approvals in the last 9 years alone. That's not marketing fluff, that's real execution. Founders consistently praise them as 'very engaged partners' with 'deep knowledge of the industry' and 'extensive networks' - the CEO testimonials are unusually glowing for biotech VCs. They've innovated with VIPEs (Venture Investments in Public Equities) for undervalued <$200M market cap biotechs, plus clinical co-development - so they're not just writing checks, they're creating new funding mechanisms. The Carlyle backing gives them serious firepower, but it also means they're playing with institutional money that has different return expectations than traditional VC funds.

ADIA isn't really a VC fund in the traditional sense - they're a massive sovereign wealth fund that occasionally writes very large checks into late-stage rounds or backs other funds. If they're interested in your startup, it's probably because you're already quite large and they're following other institutional investors. Don't expect Silicon Valley-style mentorship or network effects. They move slowly, have extensive due diligence processes, and think in decades not quarters. Great if you need patient capital and don't mind bureaucratic decision-making.

Accel is the Goldilocks of VC - not too flashy, not too sleepy, just right for founders who want solid partnership without drama. They actually know SaaS metrics better than most founders do, which can be helpful or annoying depending on your perspective. The partners genuinely stay engaged post-investment and their European presence is real, not just a satellite office. Downside: they can be slow to decide and conservative on valuations, plus their brand isn't as sexy as some other Sand Hill Road names for recruiting talent.

Accel Europe is the safe, prestigious choice - they've got the Spotify pedigree and write big checks, but they're not exactly scrappy anymore. They're excellent for founders who want a blue-chip logo on their cap table and have already proven some traction. The flip side: they can be slow to commit and their bar is high - expect multiple partner meetings and thorough due diligence. Post-investment, they're helpful with intros and strategic guidance but don't expect them to roll up their sleeves in the trenches. They're building a portfolio, not babysitting startups.

Accel India is the real deal - they've been in India since the early days and have the track record to prove it. They actually understand enterprise software and aren't just throwing money at buzzwords. Shekhar Kirani is genuinely technical and will push you on product decisions (which is good). The downside? They can be slow to decide and their bar is legitimately high - don't expect them to move fast or get excited about incremental improvements. They want category creators, not feature companies.

Acre is what happens when two solid Bessemer partners decide to go boutique — and it's worked out pretty well. Kuder and Zeplain have real pattern recognition in B2B software and actually understand the products they're backing. They're not trying to be the loudest VCs on Twitter, but they've quietly built a strong portfolio of companies that actually make money. The downside? They're still relatively small, so don't expect them to lead your Series B. But for early-stage founders who want investors who get the technical details and won't micromanage, they're a solid choice.

Act met Barry Napier "over a decade ago" and made "the largest seed investment we possibly could" - this is a fund that bets big early and doubles down on winners. They explicitly say "We have never been the loudest venture firm" and "don't want to add to the noise of VCs making it about them." Strong exit track record including SilverCloud Health (acquired by Amwell), Decawave (acquired by Qorvo), and 34 total portfolio exits. Their strategy is clear: "find the best company builders at the earliest stages and continue to back them again and again." This isn't a spray-and-pray fund - they're conviction-driven, founder-focused, and have the dry powder (€140M Fund VI) to support you through multiple rounds.

Addition is basically Lee Fixel's post-Tiger show, and he brought the same hyper-aggressive growth playbook that made Tiger famous. They move fast, write big checks, and have genuine conviction when they bite. The upside: they're not afraid to lead rounds and can be incredibly supportive during hypergrowth phases with real operational experience. The downside: they're fairly concentrated so if you're not in their wheelhouse of proven consumer/fintech growth stories, you're probably not on their radar. Fixel has a reputation for being pretty direct in board meetings, which some founders love and others find overwhelming. They're not relationship investors in the traditional sense - they're betting on your trajectory and will push hard to accelerate it.

Adobe Ventures is basically Adobe's corporate development arm disguised as a VC fund - they're scouting acquisition targets, not building a traditional venture portfolio. If your startup fits their ecosystem, you get incredible platform access and potential acquirer interest, but don't expect them to lead rounds or fight for you against other acquirers. Scott Belsky brings real credibility and founder empathy, but remember that Adobe's strategic interests will always trump pure financial returns. They're great for martech and creative tool companies that want Adobe partnership, but probably not your best bet if you're building something completely orthogonal to their business.

AEI HorizonX is basically Boeing's venture arm trying to act like a Silicon Valley fund, which creates some interesting dynamics. They have genuine aerospace expertise and can open doors that traditional VCs can't, but they move at aerospace industry speed (read: glacially slow). Their partners know the space cold and can help navigate regulatory nightmares, but don't expect quick decisions or Silicon Valley-style risk tolerance. They're particularly useful if you need intros to OEMs or help with certification processes, less useful if you need fast capital or aggressive growth strategies.

AENU is what happens when successful serial entrepreneurs get climate religion and build a fund around it. The Heilemann brothers sold DailyDeal to Google for €100M+, built Forto into a unicorn, then pivoted hard into impact investing with serious conviction. Their €170M fund closed above target in 2024, which tells you LPs are buying what they're selling. They've got the research chops (70% of deals come from internal "deep dives") and the operational experience founders actually want. But here's the thing - they're genuinely thesis-driven, not just climate-washing. They'll pass on "green" companies that don't meet their impact bar, including anything in the animal value chain or micromobility. The portfolio is performing (9 up-rounds already) and they're backing real climate tech, not feel-good sustainability theater.

Aglae is essentially Bernard Arnault's tech investment arm masquerading as a standalone VC - which is both their superpower and their Achilles heel. They have stupid money (LVMH backing means they can write big checks without blinking), phenomenal brand access through the luxury ecosystem, and a track record that includes some absolute bangers. But here's the catch: they're not really building a venture brand, they're executing family office investment strategy. The team is solid but small, and while Antoine brings decent deal flow, this isn't Sequoia-level pattern recognition. If you need growth capital and can benefit from luxury/premium brand connections, they're golden. If you want hands-on operational support or deep sector expertise, look elsewhere.

AirTree is the clear market leader in ANZ and their Canva win gives them serious credibility globally. They're genuinely founder-friendly with a reputation for being supportive through tough times, not just fair-weather investors. The partners actually know how to build companies and aren't just ex-consultants with PowerPoints. That said, they can be quite selective and their bar has risen significantly post-Canva success. They tend to move methodically rather than quickly, which can frustrate founders expecting Silicon Valley speed.

Aisling is the rare healthcare fund where the partners actually know what they're talking about - Dr. Schiff is still practicing medicine and sits on real boards, not just observer seats. Steven Elms brings serious Wall Street pedigree with 60+ transactions under his belt. They take an unusually active approach to investing and actually work closely with portfolio companies to build value and create multiple exit opportunities. The downside? Their flexible investment strategy across everything from seed to LBOs means you're competing with a much wider universe of opportunities for their attention. They're legitimate players with real exits, but don't expect hand-holding if you're just looking for a check.

AlbionVC is the grown-up in the room of UK venture - they've been doing this since 1996 and it shows in their disciplined, thesis-driven approach. Their partners project an aura of patience and take a genuinely long-term view, with reputation and consistency carrying more weight than flashy deals. Founders consistently praise Ed Lascelles specifically - Tony Pepper from Egress called him "equally important" to their success alongside the team and tech, while Quantexa's CEO said they've been privileged to work with Ed and AlbionVC from the beginning. They actually stick around - Quantexa went from first investment in 2017 to a $175m Series F at $2.6bn valuation in 2025, with AlbionVC participating in every round. The downside? They're not going to move fast on trendy deals, and if you want VC theater or ego stroking, look elsewhere.

This is the definition of corporate VC done right - except it's not really VC, it's real estate empire building with a science twist. Alexandria's secret sauce isn't just their money (they have plenty as a public REIT), it's that they own the buildings where biotech companies live and breathe. When they invest in you, they're betting you'll become their tenant, creating a beautiful conflict of interest that somehow works for everyone. They're one of the most prolific investors in the corporate VC space, but founders should know this isn't your typical Sand Hill Road partnership - they're thinking decades, not quick flips, which can be great for patient capital but frustrating if you need nimble decision-making.

This is a classic Nordic operator-turned-investor story done right. Maria Ahr brings serious Goldman pedigree and operational chops to a fund that has genuine conviction in the Northern European tech ecosystem. Their track record speaks volumes - Trustly became a fintech giant, Mentimeter is a SaaS darling, and Acast went public. What makes them different is they actually stick around post-investment and take board seats across their portfolio. The Goldman connection gives them real credibility with later-stage investors when it's time to scale. However, they're not writing massive checks - typical investments seem to be in the $3-10M range, so don't expect them to lead your Series B.

Algebra is the go-to fintech fund in Egypt and increasingly across MENA, with solid domain expertise and decent follow-on discipline. They actually understand the regulatory maze of Middle Eastern financial services, which is rare. The partners are former consultants/bankers who can be helpful on strategy but sometimes over-engineer simple problems. They're known for taking board seats seriously and pushing hard on unit economics — good if you want accountability, potentially suffocating if you prefer hands-off investors. Portfolio companies generally speak positively about their support, though some founders note they can be slow on decisions when markets get choppy.

Here's the thing - Allen & Company isn't really a VC fund, they're an investment bank that occasionally writes checks. If you're looking for traditional venture capital with board seats, operational support, and portfolio company networking, look elsewhere. However, if you're a growth-stage media or tech company looking for strategic advice, M&A guidance, or connections to corporate buyers, they're absolute gold. Their Sun Valley Conference is legendary for getting deals done, and Herbert Allen Jr. has more media industry relationships than anyone on the planet. Just don't expect them to roll up their sleeves and help you with hiring or product strategy.

Alliance is the rare Nordic VC that actually walks the walk on 'founder-friendly' instead of just talking about it. From your very first meeting, you're speaking directly with a partner — no junior associates wasting your time. Every partner has equal voting power and they make decisions by majority, but they value passionate conviction when a partner pounds the table for a deal. The sustainability angle isn't just marketing fluff — they genuinely believe it drives long-term value creation. Their exit rate is 19 percentage points higher than average VCs, which suggests they know how to pick and support winners. With offices across the Nordics and strong ties to Silicon Valley, they're well-positioned to help ambitious founders scale globally.

Alpha JWC has grown from Indonesia's first independent early-stage venture capital fund into one of the region's most active and trusted investors, reflecting how Southeast Asia's innovation economy has evolved from early experimentation to a more disciplined pursuit of sustainable growth. Their portfolio has seen 6 unicorns, 2 IPOs and 15 acquisitions including key companies like Traveloka, Kopi Kenangan and WeWork. What founders say matters: "Alpha JWC has been a true partner on our transformation journey since day 1. The support that GudangAda has received from Alpha JWC, up until this very day, far exceeds capital injection". They're hands-on to a fault - the teams literally try every dish, every app, every coffee to give candid feedback. The downside? This founder-first obsession means they might overlook business fundamentals if they fall in love with a charismatic CEO.

Altos is quietly one of the most successful funds you've never heard enough about, largely because they're not in the hype game. They're old-school value investors who actually care about unit economics and sustainable business models - revolutionary concept, I know. Their Korean and Asian market expertise is genuinely world-class, and they've had monster exits like Coupang. The partners are operator-friendly and won't try to over-manage you, but they also won't hand-hold through basic business fundamentals. If you're building something with real revenue and a path to profitability, they're gold. If you're still figuring out your business model, they're probably not your cup of tea.

Alumni Ventures is the Costco of venture capital - they've industrialized access to startup investing for wealthy alumni who want in on the action. While they've caught some great companies in their wide net and offer legitimate diversification, don't expect white-glove treatment or deep operational support. They're managing 40+ funds simultaneously, so you're more likely to get a check than a champion. The alumni angle can be genuinely helpful for customer intros and hiring, but the fund-of-funds model means less concentrated firepower when you really need it. Good for founders who want smart money without the drama, less ideal if you need hands-on board members.

Amadeus is one of the rare VCs that actually walks the walk on deep tech—they've been at it since 1997 when most funds were still figuring out what the internet was. As one founder, whose startup ContactEngine was acquired by NICE Systems, put it, landing investment from Amadeus meant securing one of "the best VCs in our space." Hermann Hauser's track record speaks for itself (he basically created ARM), and Anne Glover has built this into a proper institution. They are active investors who commonly take board seats and provide strategic advice, recruitment support, and introductions to international networks and corporate partners. The firm prides itself on being supportive yet measured, understanding when to step back and let the founders steer their company. The exit track record is genuinely impressive—multiple billion-dollar outcomes across different cycles. But here's the rub: they're extremely technical and will grill you hard on IP and defensibility. founders should be prepared for rigorous technical due diligence from Amadeus's experienced partners, many of whom bring a deep scientific background themselves.

This is Amazon's strategic arm masquerading as a VC fund - they're shopping for acquisition targets and ecosystem partners, not just financial returns. If your startup has Amazon synergies, they can be incredibly valuable with distribution, AWS credits, and Alexa integration support. But founders should know they're essentially auditing for Amazon - expect deep technical due diligence and be prepared for acquisition pressure if you succeed. The team knows voice tech cold and has real operational chops, but this isn't independent capital. They move slowly on decisions and everything gets filtered through Amazon's broader strategic priorities.

American Express Ventures is the classic corporate VC play - they write decent checks but the real question is whether you want AmEx as a strategic partner. If your business could benefit from AmEx's merchant network, customer base, or payments infrastructure, they can be genuinely valuable beyond just capital. The team is professional and knows their lanes, but like most corporate VCs, they move slower than pure financial investors and every deal gets scrutinized through the lens of strategic fit. They're not going to lead your round or fight for you in a down market the way a traditional VC might, but they're solid co-investors if the strategic alignment makes sense. Don't expect them to be your primary champion.

A16Z is the Goldman Sachs of VC - massive brand, deep pockets, but you're one of many portfolio companies competing for attention. Their platform services are legitimately helpful (recruiting, marketing, biz dev) but don't expect your GP to be in weekly contact unless you're a breakout. They write big checks and have incredible networks, but the partner you pitch might not be the one you work with day-to-day. Marc's Twitter antics can be a liability if you're building in regulated industries. Great for founders who want prestige, connections, and can handle being more independent.

a16z is the Goldman Sachs of venture capital - massive brand, deep pockets, and they know it. They'll give you more than just money: operational support, PR machine, and network access that can make or break your company. But you're getting into bed with a machine, not a boutique. Expect process, structure, and sometimes feeling like a small fish in a very big pond. They move fast on deals they want and ghost you on ones they don't. Their crypto fund has been a mixed bag despite the hype, but their AI bets are looking prescient.

A16z Bio brings serious firepower and deep pockets, but you're getting the full Andreessen treatment - meaning lots of platform resources but also high expectations and board oversight. They're genuinely helpful on business model design and scaling challenges, especially if you're building something that intersects tech and bio. The partners actually know healthcare, which is rarer than you'd think. Downside: they're not afraid to bring in new management if things go sideways, and their brand attracts competitor attention early.

a16z crypto is the 800-pound gorilla that every other crypto VC both loves and fears. They have the deepest pockets, best brand, and Chris Dixon's Twitter following, but that comes with expectations of massive outcomes. They're genuinely helpful post-investment with intros, regulatory guidance, and platform support, but they're also not afraid to lead aggressive down rounds when markets turn. The regulatory expertise they built is real and valuable. Just know that taking their money means you're playing for unicorn-or-bust outcomes.

Anicut is one of the more interesting Chennai-based funds trying to be all things to all stages, which can be both a strength and weakness. Their debt heritage gives them real conviction on unit economics - they won't fund your cash-burning dreams without serious revenue discipline. Ashvin's traditional PE background shows in their conservative deal approach, but Dhruv's addition brought some Silicon Valley swagger to the seed side. The 'founder first' messaging is genuine - they actually stick around and don't pressure for quick exits. But founders should know they're very hands-on post-investment and expect regular financial reporting that might feel heavy for early-stage companies.

Anthos is the definition of a focused, disciplined fund that actually knows their lane and stays in it. Raj Kapoor and team have legitimate enterprise software chops and don't chase shiny objects or trendy sectors they don't understand. They're genuinely helpful on enterprise sales strategy and have real relationships with CISOs and CTOs who can be early customers. The downside? They're pretty conservative on valuations and won't get into bidding wars, so if you're hot and have multiple term sheets, they might not be your highest bidder. But if you want investors who will roll up their sleeves and help you build a real business rather than just pump up your next round, they're solid.

AP Ventures is the real deal in hydrogen VC — they've been in this space since 2013, way before hydrogen became trendy. AP Ventures was founded in July 2018 as an independent venture capital fund spun out of Anglo American Platinum's successful PGM Investment Programme. It launched with US $200 million in commitments, US $100 million each from cornerstone backers Anglo American Platinum and South Africa's Public Investment Corporation. Their deep technical expertise in electrochemistry and platinum group metals gives them a genuine edge in evaluating hydrogen tech that most generalist VCs lack. The partnership between Andrew Hinkly and Kevin Eggers brings serious industrial credibility — both come from Anglo American and understand how to scale hard tech in heavy industry. At our annual meeting earlier this month, we asked some of our portfolio companies to describe what working with AP Ventures has been like over the years. The fact they actively showcase founder testimonials suggests they're confident about their portfolio relationships. They're not just writing checks — they're leveraging their industrial network to help companies navigate the complex world of industrial customers and partnerships.

Applied Ventures is the strategic arm of a $60B semiconductor equipment giant, which means they have real money and genuine industry connections that can open doors. The good news: if you're building something that touches chip manufacturing, they actually understand the space and can provide real technical validation plus introductions to every major fab. The reality check: this is corporate venture capital at its most corporate - expect longer decision cycles, internal politics affecting your deal, and strategic considerations that may not align with pure financial returns. They're genuinely helpful for hardware startups needing manufacturing partnerships, but software companies often find the relationship less valuable than promised.

AppWorks has quietly become one of Asia's most successful early-stage platforms by mastering two things most VCs struggle with: geographic focus and community building. Their "ABS" thesis (AI, Blockchain, Southeast Asia) isn't just marketing speak — they've delivered with unicorns like Dapper Labs and Animoca Brands. Jamie Lin runs a tight ship with strong conviction on web3 before it was cool, and Jessica Liu knows SEA markets better than most Silicon Valley partners know their own backyard. The accelerator program creates a genuine founder community that actually helps portfolio companies work together. However, their Taiwan-centric team may struggle with nuanced market entry in diverse SEA countries, and their heavy blockchain bet could look risky if crypto winter persists. They're operator-friendly and move fast on decisions, but expect them to push hard on regional expansion plans that might not fit your timeline.

This isn't really a venture fund in the traditional sense — it's Wall Street guys applying institutional asset management to crypto with a side hustle in early-stage deals. Founded by Wall Street veterans who saw a lack of investable crypto products that meet institutional investor standards, Arca applies decades of asset management experience and superior risk management to their investment and product innovation arms. Their real business is running crypto hedge funds and launching blockchain-based financial products like their U.S. Treasury Fund. The venture investing feels more like strategic bets to support their broader ecosystem rather than dedicated venture capital. The firm's clear focus is on creating sophisticated crypto investment vehicles for institutional clients. This suggests a product-centric approach, prioritizing the technical and regulatory rigor needed to bring digital assets into mainstream finance. Arca is likely a good match for founders building in the FinTech space, particularly those focused on blockchain infrastructure or decentralized finance. If your company aims to serve institutional markets, their expertise could be valuable.

US venture capital firm Wavemaker Partners has taken over the venture portfolio of Thailand-based Ardent Capital. Wavemaker will manage the portfolio after its merger with Ardent Ventures, the GP's venture capital arm. If you are interested in investment for your own company, or in partnering with any of the Ventures companies, please contact the team at Wavemaker. Thanks for all your support the last five years! Bangkok, July 2016. Here's the reality check: Ardent Capital basically shut down as an active fund in 2016. The founders were solid operators with real exits under their belts, but they couldn't sustain the VC model and handed their portfolio to Wavemaker. "The only time we make a dollar is when we sell a business," Vanzyl says, explaining that Ardent changes no fees whatsoever to its porfolio companies. "If that's how your business model works, we damn well better build stuff that someone wants to buy and someone will pay a lot of money for. Their no-fee model was noble but unsustainable. If you're seeing pitch decks with their name on it today, you're likely dealing with legacy portfolio management, not new investments. They built some solid companies like aCommerce, but as an active fund, they're history.

Armilar is the real deal - they've backed three unicorns (OutSystems, Feedzai, Sword Health) and have genuine deep-tech credibility spanning 25+ years. Their track record of generating returns is grounded on backing founders throughout their journey, not just writing checks. However, they work on 16 percentage points less than the average amount of lead investments, meaning they're selective but might not always lead your round. The fact they successfully raised €120M in 2025's brutal fundraising environment speaks volumes about LP confidence in their returns. The senior team has been working together for a decade with 60+ years of cumulative VC experience - this isn't a new fund with untested dynamics.